Login

Company overview with CEO | Phil Hartstein , President & CEO at FINJAN HOLDINGS, INC. 00:10:00

Share On Facebook Share On Twitter

Phil Hartstein is a President & CEO at FINJAN HOLDINGS, INC.

Recent Videos

00:10:00
Dryden Gold Secures $20M+ War Chest, Delivers High-Grade Discoveries and Expands Drill Targets Across Gold Rock District|Trey Wasser,CEO & Director,Dryden Gold
00:10:00
Mitchell Services Targets $50–60M EBITDA as Rig Utilization Drives Earnings Upside| Andrew Elf,CEO,Mitchell Services Limited
00:10:00
Lomiko Metals Reports Strong Pre-Feasibility Results with $800M NPV, Advancing High-Growth Graphite Projects|Gordana Slepcev,CEO,Lomiko Metals Inc.4
00:10:00
Generative AI Meets Wet Lab: Absci Accelerates Biologic Development with Hybrid Business Model|Sean McClain,CEO,Absci
00:10:00
Obliva Aims to Transform Lives of Children with Rare Mitochondrial Disorders|Ellen K. Donnelly ,CEO,Abliva AB7
00:10:00
Abionic Repositions Bio-HDL Therapy CCR001 for Rare Kidney and Eye Disorders with Promising Early Results|Cyrille Tupin,CEO,ABIONYX Pharma
00:10:00
Abingdon Health Reports 45% H1 Revenue Growth Amid Strategic Expansion and Large Contract Wins|Dr Chris Hand,Chairman,Abingdon Health
00:10:00
EB-101 Gene Therapy Shows Promising Results in Treating Recessive Dystrophic EB|Vishwas Seshadri,CEO,Abeona Therapeutics
00:10:00
Revolutionizing Trauma Care: How AAP’s Silver Technology is Fighting Deadly Implant Infections|Rubino Di Girolamo,CEO,aap Implantate AG
00:10:00
Revolutionizing Cancer Treatment: Tumor-Agnostic mTOR Targeting Shows Breakthrough Success in Rare and Genetic-Driven Tumors| Neil Desai, Founder, Executive Chairman ,Aadi Bioscience
00:10:00
Millions Affected, No Approved Cure: 89bio Advances New Therapy for NASH|Rohan Palekar,CEO,89bio Inc2
00:10:00
Malaria Prevention Drug Arakoda Positioned to Drive Future Growth for 60 Degrees Pharmaceuticals|Geoffrey Dow,President,60 Degrees Pharmaceuticals
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4basebio CEO Heikki Lanckriet Unveils Vision for Next-Generation Synthetic DNA and Gene Therapy Components|Heikki Lanckriet,CEO,4basebio
00:10:00
Jim Woody on Leading 180 Life Sciences: Advancing Breakthrough Biologic Therapies for Inflammation, Fibrosis, and Pain|Dr. Jim Woody,CEO,180 Life Sciences

Suggestions

00:10:00
CapMan's Strategic Updates and Ambitious Growth Targets Discussed by CEO Joakim Frimodig | Joakim Frimodig, CEO, CapMan.
00:10:00
Icetana Ltd CEO Kevin Brown and Chair Matthew Outline Global SaaS Growth Strategy | Kevin Brown , CEO , Icetana Ltd.
00:10:00
Inheritance Insights: Myra Salzer & Jack Canfield Chat | MYRA SALZER - CFP of The Wealth Conservancy, Inc.
00:10:00
Global Economic Growth and Recovery Post-Pandemic: Insights from José Martinez Sangrenetti
00:10:00
Leasing vs. Buying Equipment for Small Businesses
00:10:00
Ben Lightburn Discusses Filament Health's Mission to Standardize Natural Psychedelics | Benjamin Lightburn, CEO , Filament Health Corp.
00:10:00
Meet the Team: Wealth Managers at Anchor Pointe Wealth Management | J.Derieck Hodges - Founder & Owner of Anchor Pointe Wealth Management, LLC
00:10:00
"Engaging Singapore 2024: Chartwell Capital's Strategic Insights" | Ronald Chan, CIO, Chartwell Capital Limited
00:10:00
James Anderson: Guanajuato Silver Expands with $50M Bolanitos Deal, Building Mexico’s Fastest-Growing Silver Producer|James Anderson,CHAIRMAN & CEO,Guanajuato Silver Company Ltd
00:10:00
Understanding Financial Aid Verification: What You Need to Know
00:10:00
The Venture Reality Fund or The VR Fund, is the leading early-stage venture investor is Seed and Series A stage companies|Tipatat Chennavasin,Co-Founder and General Partner,The Venture Reality Fund/VRF
00:10:00
Fred Hu Discusses Chinese Tech Companies Outlook and Regulatory Challenges | Fred Hu, CEO, Primavera Capital Group.

© 2017 - Neuhu+